Gilead Sciences, Inc. (GILD) Shares Bought by Gateway Investment Advisers LLC
Gateway Investment Advisers LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 826,704 shares of the biopharmaceutical company’s stock after buying an additional 68,668 shares during the quarter. Gateway Investment Advisers LLC owned approximately 0.06% of Gilead Sciences worth $58,514,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Seizert Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after buying an additional 27,547 shares in the last quarter. Linscomb & Williams Inc. lifted its holdings in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 154 shares in the last quarter. Sigma Planning Corp lifted its holdings in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock worth $2,728,000 after buying an additional 2,889 shares in the last quarter. Hollencrest Securities LLC lifted its holdings in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock worth $525,000 after buying an additional 4,210 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Gilead Sciences by 61.9% in the first quarter. Candriam Luxembourg S.C.A. now owns 1,518,568 shares of the biopharmaceutical company’s stock worth $103,146,000 after buying an additional 580,801 shares in the last quarter. 73.97% of the stock is currently owned by hedge funds and other institutional investors.
In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares in the company, valued at $7,318,327.28. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is owned by company insiders.
Several equities analysts have recently commented on the stock. ValuEngine raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target on the stock. in a research report on Monday, September 4th. Finally, Wells Fargo & Company boosted their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a research report on Wednesday, September 6th. Eleven equities research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $84.29.
Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.79% during trading on Friday, hitting $83.27. 5,654,657 shares of the stock traded hands. The company has a market cap of $108.74 billion, a P/E ratio of 9.04 and a beta of 1.19. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company’s 50 day moving average price is $77.54 and its 200 day moving average price is $70.38.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.08 earnings per share. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.78 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.50%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/23/gilead-sciences-inc-gild-shares-bought-by-gateway-investment-advisers-llc.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.